Coronavirus Disease 2019 (COVID-19) Research

COVID-19 Research

The new coronavirus disease 2019 (COVID-19) outbreak is a rapidly evolving situation. There is a great deal that is unknown about this virus and research is needed to accelerate testing and therapies. While our Houston Methodist clinicians are prepared to treat patients, the Academic Institute is dedicated to coordinating clinical trials, developing new vaccines and treatment, and producing PPE, ventilators, and critical medical technologies.
Faisal N. Masud  shows Steven H. Hsu the Houston Methodist Aerosol Container
New Aerosol Design Shields Health Care Workers during Intubation

Monday, March 30, 2020- As the need for intubation increases in U.S. cases, so does the need for a new method of safe delivery for health care works. Two Houston Methodist doctors, Steven H. Hsu, MD, and Faisal N. Masud, MD, have developed a way to bring that added safety to their co-workers. They designed the Houston Methodist Aerosol Container, or HMAC, a clear plastic box-like device that shields clinicians from expelled air when intubating a patient.

Computer-generated image of a Coronavirus
FDA Approves First Plasma Therapy for Houston Methodist COVID-19 Patient

Saturday, March 28, 2020- Houston Methodist received FDA approval Saturday to become the first academic medical center in the nation to transfuse donated plasma from a recovered COVID-19 patient into a critically ill patient. 

EnMed produces a DIY N95 alternative as first real time assignment
EnMed produces a N95 alternative as first real time assignment

Thursday, March 26, 2020- As cases of coronavirus disease 2019 (COVID-19) increase and leaders across the nation put out a call for personal protective equipment for health care workers, Houston Methodist is working with its engineering partners at Texas A&M University to design a kit for creating a safe and efficient alternative to N95 masks.

Doctor looking at x-ray of chest
Houston Methodist Enrolling Patients in Two Phase 3 Clinical Studies of Safety and Antiviral Efficacy of Remdesivir to Treat COVID-19

Thursday, March 26, 2020- Houston Methodist Hospital is a participating site for two phase 3 clinical studies to evaluate the safety and efficacy of the Gilead Sciences pharmaceutical Remdesivir in adults diagnosed with coronavirus disease 2019 (COVID-19).

Intensivist and Team Study COVID-19 Protocols and Outcomes for Developing Best Practices

Wednesday, March 25, 2020- With the rapid onset of the coronavirus disease 2019 (COVID-19) pandemic, only limited national and international guidelines currently exist guiding approaches to treatment. In response to the urgent need for effective, evidence-based approaches, two Houston Methodist physicians are developing management strategies and measuring outcomes for treating COVID-19, an upper respiratory illness that can range in severity.

GeneOne Life Science and Houston Methodist will develop a COVID-19 vaccine | Houston Methodist
GeneOne Life Science and Houston Methodist to develop a COVID-19 vaccine

Tuesday, March 17, 2020- Houston Methodist researchers are partnering with GeneOne Life Science Inc. to develop an RNA vaccine against COVID-19, the novel coronavirus that has caused a global pandemic.

Live Chat Available